Merck Receives Positive EU CHMP Opinion For PREVYMIS For Prevention Of CMV Disease In High-Risk Adult Kidney Transplant Recipients And Extended 200-Day Dosing In Adult HSCT Recipients At Risk For Late CMV Infection And Disease
Portfolio Pulse from Benzinga Newsdesk
Merck has received a positive opinion from the European Union's Committee for Medicinal Products for Human Use (CHMP) for its drug PREVYMIS. The drug is intended for the prevention of Cytomegalovirus (CMV) disease in high-risk adult kidney transplant recipients and extended 200-day dosing in adult Hematopoietic Stem Cell Transplant (HSCT) recipients at risk for late CMV infection and disease.
October 17, 2023 | 10:51 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Merck's drug PREVYMIS has received a positive opinion from the EU's CHMP. This could potentially lead to increased sales and revenue for the company.
The positive opinion from the EU's CHMP for Merck's drug PREVYMIS is a significant step towards the drug's approval in the European market. This could potentially lead to increased sales and revenue for the company, positively impacting its stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100